GUJARAT INJECT (KERALA) LIMITED

CIN: L18100KL1991PLC005926

Regd Office: Bldg No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad – 678 621 **Administrative Office**: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara – 390 005 **Phones:** 09898593314. 09712193314

E-Mail: murlisnair9032@gmail.com, admin@gikl.comWebsite: www.gujaratinject.in

Date: August 14, 2023

To, **BSE Limited**Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001.

Dear Sir,

Sub: Outcome of Board meeting held today i.e. on August 14, 2023

Ref: Gujarat Inject (Kerala) Limited (Security Id/Code: GUJINJEC / 524238)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on August 14, 2023 at the Administrative Office of the Company which was commenced at 03:15 P.M. and concluded at 04:15 P.M. have, apart from other businesses, considered, approved and taken on record the unaudited Standalone Financial Results of the Company for the quarter ended on June 30, 2023 along with Limited review Report.

In this regards, we are hereby submitting the followings:

- 1. unaudited (Standalone) Financial Results for the quarter ended on June 30, 2023 and
- 2. Limited review reports;

Kindly take the same on your record and oblige us.

Thanking you

For, Gujarat Inject Kerala Limited

Murli Shivshankaran Nair Wholetime Director DIN: 02243039

Place: Vadodara

GUJARAT INJECT KERALA LIMITED

CIN: L18100KL1991PLC005926 Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621 Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, SayaJiganj , Vadodara - 390005

Statement of Unaudited Financial Results for the quarter ended on June 30, 2023

	Danki and ann	Quarter Ended			per share da Year Ende
	Particulars	30-06-2023 31-03-2023		30-06-2022	31-03-2023
Α	Date of start of reporting period	01-04-2023	01-01-2023	01-04-2022	01-04-2022
В	Date of end of reporting period	30-06-2023	31-03-2023	30-06-2022	31-03-2023
С	Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
	Revenue From Operations	4.5.0			
	Net sales or Revenue from Operations	15.37	-	4.13	17.3
II	Other Income		3.00	0.25	43.
III	Total Income (l+II)	15.37	3.00	4.38	60.6
	Expenses Control of materials assumed		-	3.20	
(b)	Cost of materials consumed	10.89		- 3.20	14.5
	Purchases of stock-in-trade Changes in inventories of finished goods, work-in-progress				
(c)	and stock-in-trade	-	-		0.0
(d)	Employee benefit expense	0.36	1.71	0.36	2.7
	Finance Costs		-	-	-
(f)	Depreciation and amortisation expense		-	-	-
(g)	Other Expenses	0.40	0.48	0.10	36.9
	Total expenses (IV)	11.65	2.19	3.66	55.0
v	Profit/(loss) before exceptional items and tax (III-IV)	3.72	0.81	0.72	5.5
	• • • • • • • • • • • • • • • • • • • •	5.72	0.01		3.5
VI	Exceptional items			-	
VII	Profit (loss) after exceptional items and before Tax (V-VI)	3.72	0.81	0.72	5.5
					1.4
-	Tax Expense	0.97	0.21	0.18	
(a) (b)	Current Tax	0.97	0.21	0.18	1.4
(c)	(Less):- MAT Credit	-			
(d)	Current Tax Expense Relating to Prior years Deferred Tax (Asset)/Liabilities	-		-	
(u)					
IX	Profit (Loss) for the period from continulng operations (VII-VIII)	2.75	0.60	0.54	4.1
x	Profit/(loss) from discontinued operations				
XI	Tax expenses of discontinued operations	-			-
	Profit/(loss) from Discontinued operations (after tax) (X-		0.00		4
XII	XI)	2.75	0.60	0.54	4.
III A	Profit(Loss) For Period Before Minority Interest	2.75	0.60	0.54	4.
	Share Of Profit / Loss of Associates and joint ventures				
	accounted for using equity method			-	
	Profit/Loss Of Minority Interset	-			
	Profit (Loss) for the period (XIII A + XIII B + XIII C)	2.75	0.60	0.54	4.
XV	Other Comprehensive Income				
	a. i). Items that will not be reclassifled to profit or loss	-	-		-
_	ii). Income tax relating to items that will not be reclassified				
	to profit or loss	-	-		-
-	b. i). Item that will be reclassifed to profit or loss	-	-		-
	ii). Income tax relating to items that will be reclassifed to				
	profit or loss	-	-		-
	*				
	Total Comprehensive income	-	-	-	
	Total Comprehensive income [Comprising Profit for the				
XVI	Period and Other comprehensive income] (XIV+XV)	2.75	0.60	0.54	4.
	reflow and other comprehensive income; (Arviav)				
XVII	Details of equity share capital				
	Paid-up equity share capital	488.48	488.48	488.48	488.
	Face value of equity share capital (Per Share)	10.00	10.00	10.00	10.
XIX	Earnings per share				
(a)	Earnings per share (not annualised for quarter ended)				
	Basic earnings (loss) per share from continuing operation	0.06	0.01	0.01	0.
	Diluted earnings (loss) per share from continuing operation	0.06	0.01	0.01	0.0
(b)	Earnings per share (not annualised for quarter ended)				
	Basic earnings (loss) per share from discontinued operation				-
	Diluted earnings (loss) per share from discontinued				
	operation				-
(c)					
(c)	Earnings per share (not annualised for quarter ended)				
	Basic earnings (loss) per share from continuing and	0.06	0.01	0.01	0.0
	discotinued operations	0.06	0.01	0.01	0.0
	Diluted earnings (loss) per share continuing and	0.06	0.01	0.01	0.0
	discotinued operations	0.00	0.01	0.01	
		0.06	0.01	0.01	

- The audited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
- As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment i.e. Trading of Cloths.
- The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For, Gujarat Inject Kerala Limited





Murli Shivshankaran Naii DIN: 02243039

Date:- 14-Aug-23 Place:- Vadodara

Wholetime Director



S. MANDAWAT & CO.

Chartered Accountants

913, Sahjanand Shopping Centre, Opp. Rajasthan Hindi High School Shahibaug Road- Ahmedabad - 380004 Phone: (O) 25620913 (M) 9426072909 Email: skmandawat@yahoo.co.in

LIMITED REVIEW REPORT ON QUARTERLY STANDALONE FINANCIAL RESULTS OF GUJARAT INJECT KERALA LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LODR) REGULATIONS, 2015 AS AMENDED, READ WITH SEBI CIRCULAR NO. CIR/CFD/CMD1/44/2019

To.

The Board of Directors of Gujarat Inject Kerala Limited,

SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara – 390 005

We have reviewed the accompanying statement of standalone unaudited financial results of Gujarat Inject Kerala Limited for the Quarter ended June 30, 2023. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 (the Listing Regulation, 2015), as amended. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed interims of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. S. Mandawat& Co. Chartered Accountants

Firm's Registration No: 118330W

CA Subhash Chandra Mandawat

Partner

Membership No. 102708

Place: Ahmedabad Date: 14-08-2023

UDIN: 23102708BGVQQQ7358